Binding Peptide Masking for Antibody Detection Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting antibodies against blood group antigens in serum, such as the Coombs test, can be non-specific and fail to differentiate between antibodies binding to blood group antigens and those binding to non-blood group antigens, especially when therapeutic antibodies like Daratumumab are present, leading to false agglutination results.
Innovation Solution
The process involves pre-treating blood cell membranes with a binding peptide specific for the first surface antigen, lacking a human Fc region, to mask the antigen and prevent non-specific binding of antibodies, allowing for the detection of antibodies against other antigens on the membranes while avoiding interference from antibodies targeting the first antigen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If the Coombs test is used to detect antibodies against blood group antigens in serum, then antibody detection is achieved, but false agglutination results occur when therapeutic antibodies like Daratumumab are present
Solution Approach 1:
A binding peptide is introduced as an intermediary substance that specifically binds to the first surface antigen on red blood cells, blocking the interaction between therapeutic antibodies (like Daratumumab) and the antigen. This mediator prevents false agglutination while allowing specific anti-blood group antibodies to be detected accurately
Solution Approach 2:
The binding peptide is added to the red blood cells before the serum is introduced, pre-blocking the first surface antigen. This preliminary action prevents subsequent non-specific binding of therapeutic antibodies, eliminating false positives before they can occur during the antibody detection process
2Measurement precision
If binding peptide is added to mask the first antigen, then non-specific antibody binding is prevented, but the complexity of the detection process increases
Solution Approach 1:
The binding peptide serves as a simple, easily added reagent that performs the masking function temporarily during the assay. It is a straightforward molecular component that can be introduced and removed without complex equipment, adding minimal complexity while significantly improving detection specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables specific detection of antibodies against blood group antigens by preventing the binding of antibodies specific to the first antigen, thereby reducing false positives and providing a clearer indication of the presence of other antibodies in the serum, even when therapeutic antibodies like Daratumumab are present.
Implementation Method 1
The binding peptide has a high specificity for a first antigen present on the blood cell membranes
Implementation Method 2
observation of binding of an added secondary labelled antibody directed against the Fc region of serum antibody
Implementation Method 3
detection of agglutination which indicated the presence of antibody directed against at least one surface antigen of the blood cell membranes
Data Source
AI summary
An analytical process for detecting antibody in human blood serum, which antibody is directed against blood group antigen, wherein the serum contains an additional antibody directed against a surface antigen, by contacting the serum to be analysed with blood cell membranes, which naturally bear surface blood group antigens, followed by detection of agglutination which indicated the presence of antibody directed against at least one surface antigen of the blood cell membranes. The agglutination reaction caused by the additional antibody is prevented, allowing the detection of anti-blood group antibody.